Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors
{{output}}
TAS-115 is a novel MET, VEGFR, FMS and PDGFR inhibitor, developed to improve the continuity of drug administration with a relatively short half-life. We assessed its tolerability, safety, pharmacokinetics, efficacy, and pharmacodynamics in patients with solid ... ...
